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blood were reduced in MI-ablation dogs, but only slight changes in ventricle
tissues Stores and infarct size.
Conclusions: The coronary sinus and great cardiac vein peripheral nerve ablation
reduce the occurrence of VA and improve ventricular electrical stability, with no
obvious effect on heart rate and systemic arterial pressure as well as infarct size.
Therefore, local cardiac sympathetic ablation may protect from ventricular arrhyth-
mias during AMI.
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Objectives: To assess the safety and biocompatibility of a novel bioabsorbable drug-
eluting PLLA/ACP scaffold for coronary applications.
Methods: A total of 12 stents, half biodegradable drug-eluting stents (BDS, n¼6),
half novel fully bioabsorbable drug-eluting scaffolds [NFBS (PowerStentAbsorb),
n¼6], were randomly implanted into the coronary arteries of 12 pigs. After the
observation by coronary angiography in the 28th day, the pigs were sacriﬁced. Stented
segments were processed for quantitative histomorphometry. Histomorphometric
analysis was performed to evaluate endometrial hyperplasia and endothelialization.
Immunohistochemical assay was applied for expression of NF-kB, a-SM-actin, CD31
and eNOS.
Results: At 28-day follow-up, no in-stent restenosis and stent thrombosis were
detected in either group. The level of VEGF and NO in NFBS group were higher
than that BDS group respectively [ (309.86  49.37) pg/ml vs. (222.04  55.16)
pg/ml, P<0.05; (129.96  9.52) mmol/L vs. (79.55  16.55) mmol /L, P<0.05].
Histological analysis indicated that inﬂammation scores of NFBS group were less
than that of BDS group (1.200.42 vs. 1.700.48, P<0.05), while endotheliali-
zation scores was greater (2.000.47 vs. 1.400.52, P<0.05). No signiﬁcant dif-
ferences in neointimal area percentage. Immunohistochemistry showed that the
expression of eNOS and CD31 in NFBS group were greater than that in BDS group
respectively (38.534.25 vs. 27.533.55, P<0.01) (29.403.84 vs. 19.783.50,
P<0.05), while NF-kB protein expression was less (22.073.18 vs. 28.593.54,
P<0.05). No signiﬁcant differences in PCNA and a-SM-actin level between two
groups.
Conclusions: NFBS based on PLLA and ACP is safe, associated with less inﬂam-
matory response and better endothelialization, improved sufﬁcient biocompatibility.
NFBS is much better than PLLA stent for coronary applications.
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Objectives: We aimed to investigate the effect of Astragaloside on cardiac function
and to search for possible mechanism in septic rats.
Methods: Fifty male Sprague-Dawley (SD) rats were randomized into Sham-opera-
tion group (Sham group, n¼10), saline group (NS group, n¼20) and Astragaloside
group (AST group, n¼20). Polymicrobial sepsis model was induced by cecal ligation
and puncture (CLP) in NS and AST group. Rats in NS group were injected with saline
(10ml/Kg) 2h after CLP and then once a day for 7 days. Rats in AST group were
injected AST (25mg/Kg) instead of saline at the same time points. Dead time of rats
was recorded every day and Cardiac function was tested by ultrasound. Serum
concentrations of monocyte chemoattractant protein-1 (MCP-1), brain natriuretic
peptide (BNP) and cardiac troponin I (cTnI) was observed. The left ventricle samples
were reserved for histomorphology. Myocardial apoptosis on the left ventricle were
detected by TUNEL staining in situ, and the changes of Bcl-2 and Bax protein were
detected by werstern blot. Meanwhile, the expression of iNOS, AMPK mRNA and
protein were tested.
Results: On day 7 after CLP, 3 out of 20 AST treated rats survived, but all rats in NS
group died. Compared with the NS group, AST group could obviously increase
ejection fraction (EF) (57.95.66 vs 70.64.02, P<0.05) but decrease the left ven-
tricular internal dimension in systole (LVIDs) (4.450.35 vs 3.440.27, P<0.05) and
MCP-1, BNP, cTnI release in serum (104.86.5 vs 89.748.2, 2.790.21 vs
2.240.17, 1.380.07 vs 0.910.05, P<0.05). Correspondingly, histomorphology
indicated that myocardial inﬂammation of AST group was comparatively mild. Also,
AST treated rats signiﬁcantly decreased myocardial apoptosis index and the expres-
sion of Bax protein was obviously decreased but markedly increased the expression of
Bcl-2 protein. Meanwhile, the mRNA expression of iNOS and AMPK in AST treated
rats was obviously increased.
Conclusions: AST could effectively extend the survival time, signiﬁcantly as-
suage the cardiac function and decrease myocardial necrosis and apoptosis inJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/Bseptic rats indused by CLP, which may be relative with the expression of iNOS
and AMPK.
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Objectives: To study histiocytic characteristics of myocardial remodeling induced by
chronic exposure to cardiotrophin-1 in Kunming mice.
Methods: Sixteen amino acids from carboxyl-terminal of mouse CT-1 were selected
and synthesized to a polypeptide (Carboxyl-terminal polypeptide of Cardiotrophin-1,
CT-1-CP), and then were injected intraperitoneally to the Kunming mice for 1 to 4
weeks (4 groups; n¼10, 5 male), the control group (n¼10, 5 male) received intra-
peritoneal injection of physiological saline for 4 weeks. At every end point of injection
the body and heart were weighted, and the hearts tissues samples were isolated and
embedded in parafﬁn for preparing tissue section. The HE and MASSON staining
were used for dynamic morphological histological analysis.
Results: The increase of body weight at ﬁrst and second week was higher in the
control group than that of the CT-1-CP-injected groups, but was signiﬁcantly
lower than that of the latter at third (t¼4.821, P<0.01) and forth week (t¼2.019,
P<0.05). and the body weight of the four-week group had exceeded slightly the
control group; The heart weight of mice in CT-1-CP-injected groups were higher
than that of the control group, but the heart to body weight ratio has no signiﬁcant
difference among them (F¼1.0833, P > 0.05). Intraperitoneal injection of CT-
1-CP one weeks later, the mice began to appear enlarging of ventricular cavity
and thinning of the ventricular wall, and the derangement myoﬁbril and the
blurred cross striation complicated with uneven staining of cytoplasm, which were
scattered in the ventricular wall, were detected. After 2 weeks, the anatomical
change of ventricles became deteriorated and local hypertrophy of ventricular wall
appeared, and the focuses of pathological changes of cardiomyocytes increased. 3,
4 weeks later, the lesion was more obvious and the scope of focuses gradually
expanded. In focuses with serious pathological change some myoﬁbrils were
fragmented and some sarcomeres were partially or wholly lost. Masson staining
also shows exaggerated growth of the ﬁbril-connective tissues surrounding
myoﬁbrils and in the spaces where the myoﬁbril array disturbed or sarcomere
defected.
Conclusions: Long-term exposure to CT-1-CP could promote cardiac hypertrophy
and lead to cardiac remodeling in Kunming mice as well as the ultrastructure damage
of cardiomyocyte in remodeled myocardial tissues, otherwise, induced the hyperplasia
of ﬁbril-connective tissues.
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Objectives: Oral glucocorticoids can prevent Acute Mountain Sickness (AMS);
however, these drugs are associated with multiple systemic side effects. The effects of
inhaled Budesonide, an alternative AMS therapy, remain unknown.
Methods: The 80 healthy young male plain residents (17w33 years old) were
recruited. Potential participants were excluded if they had a high altitude (> 2500 m)
exposure history in the last year or organic diseases such as congenital heart disease,
arrhythmia, liver or kidney dysfunction, psychological or neurological disorder. The
subjects were randomly assigned to receive inhalation of budesonide (BUD, 200 mg,
bid), procaterol tablet (PT, 25 mg, bid), inhalation of budesonide/fomoterol (BUD/FM,
160 mg/4.5 mg, bid) or placebo (1 tablet, bid) (n ¼ 20 subjects, respectively). Subjects
began treatment three days before an ascent to 3700 m from 500 m plain within 2.5 h
by air. The treatment stopped after arrival. The Lake Louis AMS questionnaire, blood
pressure (BP), heart rate (HR), and oxygen saturation (SpO2) were scored at 20 h, 72
h, and 120 h following exposure to high altitude. Pulmonary function was measured
after 20 h exposure.
Results: Compared with placebo, BUD reduced the incidence of AMS (70% vs. 25%
at 20 h after exposure, P< 0.05; 10% vs. 5% at 72 h, P > 0.05; 10% vs. 5% at 120 h,
P > 0.05) without side effects, relative risk is 0.357, and the attributable risk is
0.45. SpO2 was higher in BUD, BUD/FM and PT groups compared to placebo at 20 h
(P ¼ 0.0001). All subjects’ SpO2 dropped following ascent (98.1% to 88.12%,
P< 0.01) and increased gradually but still lower at 120 h than that at plain
(92.04% vs. 98.1%, P< 0.01). Pulmonary function was not different among the four
groups at 20 h. There was no HAPE or HACE reported.
Conclusions: BUD can prevent AMS without side effects. The alleviation of AMS
may be related to increased SpO2 rather than pulmonary function.
The registration number of this clinical trial was ChiCTR-PRC-12002748.asic and Translational Medicine C69
